Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in phase 3 testing.

It is playing catch-up with a rival Lp(a) targeting antisense drug from Novartis and development partner Akcea, called pelacarsen, which is already in a phase 3 trial called HORIZON with major ...

It gives patients hope." One of those experimental drugs is called pelacarsen, from drugmaker Novartis. Earlier studies showed it significantly drove down Lp(a) levels in 98% of people taking it. The ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

Novartis' drug segment is poised for steady ... close to $1 billion for remibrutinib (multiple sclerosis data in 2026), pelacarsen (cardiovascular outcomes data in 2025), and rare disease drug ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication. The Swiss drugmaker ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...

Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live webcast. [Operator instructions] With that, I would like to hand over to Ms. Sloan ...